Literature DB >> 16466964

RNA interference in cancer.

Andrei L Gartel1, Eugene S Kandel.   

Abstract

In the recent years, RNA interference (RNAi) has emerged as a major regulatory mechanism in eukaryotic gene expression. The realization that changes in the levels of microRNAs are directly associated with cancer led to the recognition of a new class of tumor suppressors and oncogenes. Moreover, RNAi has been turned into a potent tool for artificially modulating gene expression through the introduction of short interfering RNAs. A plethora of individual inhibitory RNAs as well as several large collections of these reagents have been generated. The systems for stable and regulated expression of these molecules emerged as well. These tools have helped to delineate the roles of various cellular factors in oncogenesis and tumor suppression and laid the foundation for new approaches in gene discovery. Furthermore, successful inhibition of tumor cell growth by RNAi aimed at oncogenes in vitro and in vivo supports the enthusiasm for potential therapeutic applications of this technique. In this article we review the evidence of microRNA involvement in cancer, the use of short interfering RNAs in forward and reverse genetics of this disease, and as well as both the benefits and limitations of experimental RNAi.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466964     DOI: 10.1016/j.bioeng.2006.01.002

Source DB:  PubMed          Journal:  Biomol Eng        ISSN: 1389-0344


  52 in total

1.  A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors.

Authors:  Elisabeth Simboeck; Anna Sawicka; Gordin Zupkovitz; Silvia Senese; Stefan Winter; Franck Dequiedt; Egon Ogris; Luciano Di Croce; Susanna Chiocca; Christian Seiser
Journal:  J Biol Chem       Date:  2010-10-14       Impact factor: 5.157

Review 2.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

Review 3.  Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?

Authors:  Dirk Grimm; Mark A Kay
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 4.  Target validation to biomarker development: focus on RNA interference.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  Inhibition of latent transforming growth factor-beta1 activation by lentivirus-mediated short hairpin RNA targeting the CD36 gene in NR8383 cells.

Authors:  Xin Wang; Ying Chen; Lina Lv; Jie Chen
Journal:  Mol Biol Rep       Date:  2009-06-10       Impact factor: 2.316

6.  The evidence for a microRNA product of human DROSHA gene.

Authors:  Peter Mechtler; Sydney Johnson; Hannah Slabodkin; Amir B Cohanim; Leonid Brodsky; Eugene S Kandel
Journal:  RNA Biol       Date:  2017-09-05       Impact factor: 4.652

7.  Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.

Authors:  A K Nalla; B Gorantla; C S Gondi; S S Lakka; J S Rao
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

8.  rna interference targeting p110β reduces tumor necrosis factor-alpha production in cellular response to wear particles in vitro and osteolysis in vivo.

Authors:  Jian-bin Huang; Yue Ding; Dong-sheng Huang; Wei-ke Zeng; Zhi-ping Guan; Mao-lin Zhang
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

9.  PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma.

Authors:  Carolyn L Waite; Charles M Roth
Journal:  Bioconjug Chem       Date:  2009-09-23       Impact factor: 4.774

10.  Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice.

Authors:  Jing Li; Yun-Feng Piao; Zheng Jiang; Li Chen; Hai-Bo Sun
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.